Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis and Natalizumab.

Domenico Fiore1

  • 1Viale Madonna delle Grazie, Piove di Sacco, Italia. domenicofiore@libero.it

American Journal of Therapeutics
|December 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and treatment of multiple sclerosis and amyotrophic lateral sclerosis: neuropathies from Bordetella pertussis.

American journal of therapeutics·2003
Same journal

Abrocitinib as a Novel Therapeutic Option for Elastolytic Giant Cell Granuloma: A Case Report.

American journal of therapeutics·2026
Same journal

Dupilumab for Lichen Amyloidosis in an Elderly Multimorbid Patient.

American journal of therapeutics·2026
Same journal

Deucravacitinib for Generalized Pustular Psoriasis and Comorbid Polymyositis: Dual Efficacy and Favorable Safety.

American journal of therapeutics·2026
Same journal

Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.

American journal of therapeutics·2026
Same journal

Do Not Treat a Sequencing Report: Therapeutic Stewardship in Endometrial Microbiome Testing.

American journal of therapeutics·2026
Same journal

Right Side Accessory Pathway Mediated Cardiomyopathy Treated with Amiodarone: First Adult Case Report.

American journal of therapeutics·2026
See all related articles

Natalizumab (NTZ), an immune modulator for multiple sclerosis (MS), was withdrawn due to serious adverse events. Its efficacy and risks vary by MS type, with potential utility in early progressive MS combined with antibiotics.

Area of Science:

  • Neuroimmunology
  • Pharmacology
  • Clinical Neurology

Background:

  • Natalizumab (NTZ) is an elective adhesion molecule inhibitor developed for relapsing-remitting multiple sclerosis (MS).
  • NTZ was suspended due to two cases of progressive multifocal leukoencephalopathy (PML) but later recommended for MS treatment.
  • NTZ functions by inhibiting immune cell adhesion to the endothelium and reducing immune complex precipitation in the central nervous system (CNS).

Purpose of the Study:

  • To evaluate the efficacy and safety of Natalizumab (NTZ) in different forms of multiple sclerosis (MS).
  • To analyze the mechanism of action of NTZ concerning circulating immune complexes (CICs) and antibody production.
  • To determine the appropriate use of NTZ in conjunction with antibiotic therapy for MS.

Main Methods:

Related Experiment Videos

  • Analysis of Natalizumab's (NTZ) mechanism of action involving immune cell adhesion and CICs.
  • Review of clinical outcomes and adverse events associated with NTZ treatment in MS patients.
  • Assessment of NTZ's interaction with antibiotic treatments in progressive MS.

Main Results:

  • NTZ is considered ineffective in remittent MS due to the absence of CICs between attacks.
  • NTZ treatment may lead to lateral amyotrophic sclerosis or PML in chronic-progressive MS.
  • NTZ shows potential benefit in the initial two months of antibiotic treatment for progressive MS to prevent new lesions.

Conclusions:

  • The use of Natalizumab (NTZ) in MS requires careful consideration of the disease subtype and potential risks.
  • NTZ may be beneficial in early progressive MS when combined with long-term antibiotic therapy to halt toxin production.
  • Further research is needed to fully elucidate NTZ's role and optimize its application in MS management.